Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

Background Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been
associated with relapse prevention through the clearance of P. vivax parasitemia and …

Background Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal
dosing regimen remains unclear. We undertook a systematic review and individual patient …

Background Malaria causes a reduction in haemoglobin that is compounded by primaquine,
particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The …

Background Plasmodium vivax infections are an important contributor to the malaria burden
worldwide. The World Health Organization recommends a 14‐day course of primaquine …

Background A 14-day course of primaquine is used for radical cure of Plasmodium vivax
and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after …

Primaquine (PQ) is recommended to prevent relapses in patients with Plasmodium vivax
malaria infection. However, treatment with PQ causes methemoglobinemia. In this study, we …

Background Malaria caused by Plasmodium vivax requires treatment of the blood‐stage
infection and treatment of the hypnozoites that develop in the liver. This is a challenge to …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …